Biosimilar developer Biocon has received the FDA’s Form 483 after a preapproval inspection of its Bangalore manufacturing facility resulted in 7 observations. The FDA issues Form 483 when an investigator conducting an inspection has observed conditions that may constitute violations of the Food, Drug, and Cosmetic Act or related acts.
Biosimilar developer Biocon has received the FDA’s Form 483 after a preapproval inspection of its Bangalore manufacturing facility resulted in 7 observations. The FDA issues Form 483 when an investigator conducting an inspection has observed conditions that may constitute violations of the Food, Drug, and Cosmetic Act or related acts.
In the same week, Biocon revealed, it received a preliminary report from a European regulatory inspection of the same facility. The European report notes 6 “major” observations. A spokesperson for the company said in a statement that Biocon will respond to both of the regulatory bodies with corrective and preventive action plans in a timely fashion.
These regulatory setbacks for Biocon are not the first in recent days for Biocon; separately, in February 2018, Biocon received a Form 483—noting 6 observations—for its manufacturing facility in Malaysia, where it plans to manufacture its insulin products, and the Bangalore facility, which manufactures monoclonal antibodies, was the subject of a 2017 Form 483, as well as a 2017 French National Agency for Medicines and Health Products Safety non-compliance statement.
The French inspection found 35 problems, 11 of which were deemed major, and related to environmental monitoring, training, cross-contamination risks, cleaning validation, and process validation, among others. On the heels of that noncompliance statement, Biocon withdrew from the European Medicines Agency its applications for 2 biosimilars, trastuzumab and pegfilgrastim, saying that the regulatory body would reinspect the facility after corrective and preventive actions had been undertaken, and that Biocon would resubmit its applications after a new inspection had been completed.
Currently, the FDA has approved Biocon’s trastuzumab biosimilar, Ogivri, although the drug has not yet been launched in the United States. The FDA rejected another proposed Biocon biosimilar, MYL-1401H, a pegfilgrastim product referencing Neulasta. According to Biocon, the FDA’s Complete Response Letter (CRL) for the proposed drug relates to “data from facility requalification activities” after recent modifications to its manufacturing plant, and the CRL did not raise questions concerning the drug’s biosimilarity, pharmacokinetic or pharmacodynamic data, clinical data, or immunogenicity.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.